Shmagin v. Urigen Pharmaceuticals, Inc.

Filing 57

ORDER re 56 Joint Case Management Statement filed by Urigen Pharmaceuticals, Inc. Signed by Magistrate Judge Jacqueline Scott Corley on 8/29/2013. (ahm, COURT STAFF) (Filed on 8/29/2013)

1
2
3
4
5
6
7
8
9
10
11
12
13
14

Lawrence H. Stone (SBN 146797)
Lindsay L. Ryan (SBN 258130)
David Z. Feingold (SBN 280194)
725 S. Figueroa Street, Suite 2500
Los Angeles, CA 90017
Telephone: [phone]
Facsimile: [phone]
[e-mail]
[e-mail]
[e-mail]
Attorneys for Defendant and Cross-Complainant
URIGEN PHARMACEUTICALS, INC.
AnnaMary E. Gannon (SBN 92175)
[e-mail]
Barbara L. Harris Chiang (SBN 206832)
[e-mail]
DILLINGHAM & MURPHY LLP
601California St., Suite 1900
San Francisco, CA 94108
Telephone: [phone]
Facsimile: [phone]
Attorneys for Plaintiff
MARTIN E. SHMAGIN

15

UNITED STATES DISTRICT COURT

16

NORTHERN DISTRICT OF CALIFORNIA

17
18

MARTIN E. SHMAGIN

19
20
21
22

Plaintiff,
v.
URIGEN PHARMACEUTICALS, INC.

CASE NO.: 12-cv-2630 JSC
Hon. Jacqueline Scott Corley
JOINT CASE MANAGEMENT
CONFERENCE STATEMENT

23
24
25

August 29, 2013
1:30 p.m.
“F”

Complaint Filed:
FAC Filed:
FAC Served:
Trial Date:

Defendants.

Date:
Time:
Courtroom:

May 22, 2012
June 1, 2012
June 15, 2012
October 7, 2013

26
27
28
CASE NO.: 12 2630 JSC

JOINT CASE MANAGEMENT
CONFERENCE STATEMENT

1

URIGEN PHARMACEUTICALS, INC.,

2
3
4
5

Cross-Complainant,
v.
MARTIN E. SHMAGIN, an Individual;
and DOES 1 through 10, inclusive,
Cross-Defendants.

6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
CASE NO.: 12 2630 JSC

JOINT CASE MANAGEMENT
CONFERENCE STATEMENT

1

Defendant and Cross-Complainant URIGEN PHARMACEUTICALS, INC.

2

(“Defendant” or “Cross-Complainant” or “Urigen”) and Plaintiff MARTIN E.

3

SHMAGIN (“Plaintiff”), by and through their respective counsel of record, hereby

4

submit the following update in advance of the scheduled Case Management Conference.

5

After extensive negotiations and diligent efforts to finalize the complex settlement

6

agreement reached in this matter, there remain only two provisions for which the parties

7

are working to finalize the language. The parties anticipate resolving these issues shortly,

8

and thereafter executing the Settlement Agreement, however, the agreement will not

9

likely be executed in time to file a Request for Dismissal in advance of tomorrow’s

10

hearing. Accordingly, the parties would jointly request that the Court briefly continue the

11

scheduled Case Management Conference by fourteen (14) days to September 10, 2013.

12

Date:

August 28, 2013

JACKSON LEWIS, LLP

13
14

By:

/s/ Lawrence H. Stone
Lawrence H. Stone
Lindsay L. Ryan
David Z. Feingold

15
16

Attorneys for Defendant and CrossComplainant
URIGEN PHARMACEUTICALS, INC.

17
18
19

Date:

August 28, 2013

Dillingham & Murphy, LLP

20
21

By:

/s/ Barbara L. Harris Chiang
AnnaMary E. Gannon
Barbara L. Harris Chiang

22
23

Attorneys for Plaintiff
MARTIN E. SHMAGIN

24

The case management conference is continued to 9/12/13 at 1:30 p.m.

NO

28

TED

GRAN

RT

3N

ER

H

CASE NO.: 12 2630 JSC

Judge Ja

cquelin

e Scott

Corley

F
D IS T IC T O
R

R NIA

S

UNIT
ED

27

S DISTRICT
TE
C
TA

RT
U
O

Dated: 8/29/2013

FO

26

LI

4844-5925-9925, v. 1

A

25

C

JOINT CASE MANAGEMENT
CONFERENCE STATEMENT